Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features

Adv Anat Pathol. 2011 Nov;18(6):415-37. doi: 10.1097/PAP.0b013e318234ab18.

Abstract

This review focuses on the most common diagnostic pitfalls and helpful morphologic and immunohistochemical markers in the differential diagnosis between the different subtypes of endometrial carcinomas, including: (1) endometrioid versus serous glandular carcinoma, (2) papillary endometrioid (not otherwise specified, villoglandular and nonvillous variants) versus serous carcinoma, (3) endometrioid carcinoma with spindle cells, hyalinization, and heterologous components versus malignant mixed müllerian tumor, (4) high-grade endometrioid versus serous carcinoma, (5) high-grade endometrioid carcinoma versus dedifferentiated or undifferentiated carcinoma, (6) endometrioid carcinoma with clear cells versus clear cell carcinoma, (7) clear cell versus serous carcinoma, (8) undifferentiated versus neuroendocrine carcinoma, (9) carcinoma of mixed cell types versus carcinoma with ambiguous features or variant morphology, (10) Lynch syndrome-related endometrial carcinomas, (11) high-grade or undifferentiated carcinoma versus nonepithelial uterine tumors. As carcinomas in the endometrium are not always primary, this review also discusses the differential diagnosis between endometrial carcinomas and other gynecological malignancies such as endocervical (glandular) and ovarian/peritoneal serous carcinoma, as well as with extra-gynecologic metastases (mainly breast and colon).

Publication types

  • Review

MeSH terms

  • Adenocarcinoma, Clear Cell / pathology
  • Biomarkers, Tumor / analysis
  • Carcinoma, Endometrioid / pathology
  • Cyclin-Dependent Kinase Inhibitor p16 / analysis
  • Cystadenocarcinoma, Serous / pathology
  • Endometrial Neoplasms / pathology*
  • Endometrial Neoplasms / secondary
  • Female
  • Humans
  • Tumor Suppressor Protein p53 / analysis
  • Uterine Neoplasms / pathology

Substances

  • Biomarkers, Tumor
  • Cyclin-Dependent Kinase Inhibitor p16
  • Tumor Suppressor Protein p53